RSPI RESPIRERX PHARMACEUTICALS

RespireRx Pharmaceuticals Inc. Announces Publication of Preclinical Results Supporting the Use of Ampakines in the Treatment of Spinal Cord Injury

RespireRx Pharmaceuticals Inc. Announces Publication of Preclinical Results Supporting the Use of Ampakines in the Treatment of Spinal Cord Injury
EN
06/10/2020

Underlying

RSPIRESPIRERX PHARMACEUTICALS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on RESPIRERX PHARMACEUTICALS

 PRESS RELEASE
Free
RSPI RESPIRERX PHARM...

RespireRx Pharmaceuticals Inc. CFO and CEO Issue Letter to Stockholder...

RespireRx Pharmaceuticals Inc. CFO and CEO Issue Letter to Stockholders, Stakeholders, Strategic and Potential Strategic Partners and Other Interested Parties Glen Rock, N.J., Nov. 20, 2025 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (RespireRx or the Company), and its subsidiaries, EndeavourRx LLC (EndeavourRx) and ResolutionRx Ltd (ResolutionRx), collectively, the RespireRx Group, leaders in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, today provides a progress and status report to its stoc...

November 20, 2025 1 EN
 PRESS RELEASE
Free
RSPI RESPIRERX PHARM...

RespireRx Pharmaceuticals Inc. Announces NIH/NINDS Grant Award and Ame...

RespireRx Pharmaceuticals Inc. Announces NIH/NINDS Grant Award and Amended and Restated Patent License Agreement Glen Rock, N.J., Nov. 19, 2025 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce the receipt of a Notice of Award of a grant from the NIH/NINDS and entry into an Amended and Restated Patent License Agreement with the University of Wisconsin Research Foundation. Summary of the ...

November 19, 2025 1 EN
 PRESS RELEASE
Free
RSPI RESPIRERX PHARM...

RespireRx Pharmaceuticals Inc. Announces SEC Order Making Findings and...

RespireRx Pharmaceuticals Inc. Announces SEC Order Making Findings and Revoking Registration of Securities and Future Plans with respect to its Common Stock Glen Rock, N.J., Nov. 18, 2025 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (“RespireRx”, “RSPI”, “Respondent” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, announces the receipt of an Order Making Findings and Revoking Registration of Securities Pursuant to Section 12(j) of the Securities Exchange Act of 1934...

November 18, 2025 1 EN
 PRESS RELEASE
Free
RSPI RESPIRERX PHARM...

RespireRx Pharmaceuticals Inc. Announces Commencement of Rule 506(c) P...

RespireRx Pharmaceuticals Inc. Announces Commencement of Rule 506(c) Private Placement Glen Rock, N.J., Nov. 18, 2025 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce the commencement of a Regulation D, Rule 506(c) exempt offering of securities, across the three entities of the RespireRx Group, RespireRx, EndeavourRx LLC and ResolutionRx Ltd (collectively, the RespireRx Group). The targe...

November 18, 2025 1 EN
 PRESS RELEASE
Free
RSPI RESPIRERX PHARM...

RespireRx Pharmaceuticals Inc. CFO and CEO Issue Letter to Stockholder...

RespireRx Pharmaceuticals Inc. CFO and CEO Issue Letter to Stockholders, Stakeholders, Strategic and Potential Strategic Partners and Other Interested Parties Glen Rock, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, today provides a progress and status report to its stockholders, stakeholders, strategic partners as well as other interested parties. Dear Stockholders, Stakeholders, Strat...

February 10, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch